A TWO-PART, SEAMLESS, MULTICENTER, RANDOMIZED, OPEN LABEL, ADAPTIVE PHASE II/III STUDY OF THE BLOOD-BRAIN BARRIER PENETRANT RO7771950 VERSUS TUCATINIB, BOTH IN COMBINATION WITH TRASTUZUMAB AND CAPECITABINE, IN PATIENTSITH PRETREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER, WITH OR WITHOUT CENTRAL NERVOUS SYSTEM METASTASES
Phase: Phase II-III clinical trials
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Oncologia Medica 1
Drug: RO7771950 (ZN-A-1041)
Pathologies: Breast cancer
ClinicalTrials.gov: Read the details about clinical trials
Multicenter, randomized, open-label clinical study evaluating RO7771950 (a HER2-selective tyrosine kinase inhibitor [TKI]), a drug capable of crossing the blood–brain barrier, versus tucatinib, both in combination with trastuzumab and capecitabine, in patients with previously treated, unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases.The study consists of two parts: a dose-selection phase (Part I), including an interim analysis to identify the most appropriate dose of RO7771950, and a confirmatory phase (Part II), in which the efficacy of the selected treatment is compared with standard therapy. During Part I, preliminary results (objective response rate) are used to determine whether to proceed to Part II.
Last update: 14/07/2026